Please login to the form below

Not currently logged in
Email:
Password:

Par Pharmaceutical

This page shows the latest Par Pharmaceutical news and features for those working in and with pharma, biotech and healthcare.

Hikma pays $2.6bn for Boehringer’s US generics unit

Hikma pays $2.6bn for Boehringer’s US generics unit

There have been a number of generic deals this year, including Pfizer's $15bn deal for Hospira in February and Endo International's $8bn purchase of Par Pharmaceutical in May.

Latest news

  • Perrigo warming to Mylan - at the right price Perrigo warming to Mylan - at the right price

    Most recently, Endo has just agreed an $8.1bn deal to acquire Par Pharmaceutical and boost its generics business. .

  • Endo buys Par for $8bn as M&A mania marches on Endo buys Par for $8bn as M&A mania marches on

    Endo is the latest to step up, offering just over $8bn for Par Pharmaceutical in order to boost its generics business. ... The acquisition comes after Endo tried and failed to merge with Salix Pharmaceutical earlier this year, eventually losing out to

  • Par buys Anchen in $410m deal

    US-based Par Pharmaceutical is to purchase generic medicines manufacturer Anchen Pharmaceuticals. ... Par Pharmaceutical Companies is to acquire Anchen Pharmaceuticals, a privately owned speciality pharmaceutical company focused on developing and

  • Par to acquire Indian generics firm

    US-based Par Pharmaceutical has entered into a definitive agreement to acquire India's Edict Pharmaceuticals, a privately held developer and manufacturer of solid oral dosage generic pharmaceuticals. ... The US-based speciality pharma company Par

  • Pozen files to block generic migraine drug

    Pozen has filed a motion to block Par Pharmaceutical from launching a generic version of the migraine drug Treximet, which is marketed in the US by GlaxoSmithKline. ... Pozen has filed a motion to block Par Pharmaceutical from launching a generic version

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    510. JHP/ Par Pharmaceuticals. Company acquisition. Par acquires JHP, a leading specialty pharmaceutical company of branded and generic sterile injectables.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Par hires Antonio Pera as commercial head Par hires Antonio Pera as commercial head

    Follows acquisition of Pera’s former company JHP Pharmaceuticals. Par Pharmaceutical Companies has appointed Antonio Pera as chief commercial officer, leading the company's newly-integrated sales and marketing division following ... Tony has enjoyed a

  • Eisai appoints Lynn Kramer chief clinical officer Eisai appoints Lynn Kramer chief clinical officer

    Prior to joining Eisai, Dr Krammer had already spent more two decades in the pharmaceutical industry,  serving at companies such as PAR Pharmaceutical, Ciba Geigy and Novartis.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics